Stock Report: Santarus Inc. (SNTS) Report Updated: May 13, 2013 | Print This Page

Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company sells metformin hydrochloride extended release tablets under the Glumetza name and bromocriptine mesylate tablets under the CYCLOSET name, which are indicated to treat type 2 diabetes; and omeprazole/sodium bicarbonate capsules and powder for oral suspension under the Zegerid name primarily to pharmaceutical wholesale distributors. Its products under development include Budesonide MMX, which completed two Phase III clinical studies for the treatment of ulcerative colitis; Rhucin (recombinant human C1 inhibitor) under Phase IIIb clinical study for the treatment of acute attacks of hereditary angioedema, and under Phase II proof study for the treatment of early antibody mediated rejection; Rifamycin SV MMX, a Phase III clinical program for the treatment of patients with travelers’ diarrhea, as well as for other diseases with a bacterial component in the intestine; and SAN-300 under Phase I clinical study for the treatment of rheumatoid arthritis. The company was founded in 1996 and is based in San Diego, California.